The California Supreme Court has ruled that Gilead Sciences cannot face negligence claims for allegedly delaying the release of a safer HIV drug while continuing to market an older treatment with more harmful side effects.
In a 6-1 decision, the justices reversed a lower appellate ruling that had expanded manufacturers’